Oxford BioDynamics (LON:OBD) Trading Down 1.8% – What’s Next?

Oxford BioDynamics Plc (LON:OBD)’s share price traded down 1.8% on Tuesday . The company traded as low as GBX 0.08 and last traded at GBX 0.11. 29,929,361 shares were traded during mid-day trading, an increase of 80% from the average session volume of 16,632,014 shares. The stock had previously closed at GBX 0.11.

Oxford BioDynamics Price Performance

The company has a fifty day simple moving average of GBX 0.18 and a two-hundred day simple moving average of GBX 0.22. The stock has a market capitalization of £4.63 million, a P/E ratio of -0.54 and a beta of 0.42. The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61.

Oxford BioDynamics (LON:OBD) last released its earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) EPS for the quarter. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.